N-(1-甲基-1H-苯并[d]咪唑-2-基)-乙酰胺 | 7035-71-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: N-(1-甲基-1H-苯并[d]咪唑-2-基)-乙酰胺
• 英文名称: 2-(acetylamino)-1-methylbenzimidazole
• 英文别名: N-(1-methyl-1H-benzoimidazol-2-yl)-acetamide；2-Acetamino-1-methyl-benzimidazol；1-Methyl-2-acetamidobenzimidazol；N-Methyl-2-acetamidobenzimidazol；N-(1-methyl-1H-benzimidazol-2-yl)acetamide；N-(1-methylbenzimidazol-2-yl)acetamide
• CAS: 7035-71-4
• 化学式: C₁₀H₁₁N₃O
• mdl: MFCD03033887
• 分子量: 189.217
• InChiKey: KXTVSMVRPHAFDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  46.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(1-甲基-1H-苯并[d]咪唑-2-基)-乙酰胺 以80%的产率得到
  参考文献：
  名称：

  ANISIMOVA V. A.; SIMONOV A. M., XIMIYA GETEROTSIKL. SOEDIN. , 1976, HO 1, 121-125

  摘要：

  DOI：
• 作为产物：
  描述：

  3--5-methyl-1,2,4-oxadiazole 以 甲醇 为溶剂， 反应 0.5h， 以30%的产率得到3-(acetylamino)-1-methylindazole
  参考文献：
  名称：

  Photoinduced Molecular Rearrangements. The Photochemistry of Some 1,2,4-Oxadiazoles in the Presence of Nitrogen Nucleophiles. Formation of 1,2,4-Triazoles, Indazoles, and Benzimidazoles

  摘要：

  The photochemistry of some 3,5-disubstituted 1,2,4-oxadiazoles in the presence of nitrogen nucleophiles [external, such as added amines or hydrazines, or internal, such as an o-aminophenyl moiety at C(3) of the oxadiazole ring] has been investigated. In the irradiation of 5-amino-(or 5-N-substituted amino) 3-phenyl-1,2,4-oxadiazoles in the presence of aliphatic primary amines (or ammonia), photolytic species arising from heterolytic cleavage of the ring O-N bond capture the nucleophilic reagent to give open-chain intermediates, which develop into 1,2,4-triazolin-5-ones. Similarly, irradiations of 3,5-diphenyl-, 3-methoxy-5-phenyl-, and 5-methyl-3-phenyl-1,2,4-oxadiazoles gave 1,2,4-triazoles. In the same context, irradiations of representative substrates in the presence of hydrazines have been also investigated. In the irradiation of 3-(o-aminophenyl)-5-methyl-, 3-[o-(methylamino)phenyl]-5-methyl-, and 3-(o-aminophenyl)-5-phenyl-1,2,4-oxadiazoles, concomitant formation of indazoles and benzimidazoles, presumably arising from a common photolytic species, has been observed. Some mechanistic aspects have been considered, and possible applications in synthesis have been pointed out.

  DOI：

  10.1021/jo960765i

文献信息

• Design and synthesis of N-benzimidazol-2-yl-N'-sulfonyl acetamidines
  作者：Nadezhda A. Rupakova、Vasiliy A. Bakulev、Uwe Knippschild、Balbina García-Reyes、Oleg S. Eltsov、Grigoriy P. Slesarev、Nikolai Beliaev、Pavel A. Slepukhin、Lydia Witt、Christian Peifer、Tetyana V. Beryozkina

  DOI：10.24820/ark.5550190.p010.200

  日期：——

  N-Sulfonyl-N'-benzimidazol-2-yl acetamidines have been designed as CK1 inhibitors. Binding modes in the ATP pocket of CK1 were determined by molecular modeling. The synthetic approach involves sequential acylation of 2-aminobenzimidazoles followed by reaction of amides with Lawesson’s reagent and iminosulfonylation of thioamides with sulfonyl azides. The iminosulfonylation was carried out in boiling

  N-磺酰基-N'-苯并咪唑-2-基乙脒被设计为CK1抑制剂。CK1 ATP 袋中的结合模式由分子模型确定。合成方法包括 2-氨基苯并咪唑的顺序酰化，然后酰胺与劳森试剂反应，硫代酰胺与磺酰叠氮化物的亚氨基磺酰化。亚氨基磺酰化在沸腾的乙醇中进行，叠氮化物和硫代酰胺的比例相等。测试合成的化合物在体外抑制 CK1 同种型和抑制肿瘤细胞系生长的能力。在合成的化合物中，有两种产物对 CK1δ 和 CK1ε 表现出抑制能力。
• Substituted Imidazopyridinyl-Aminopyridine Compounds
  申请人：Ashwell Mark A.

  公开号：US20110172203A1

  公开（公告）日：2011-07-14

  The present invention relates to substituted imidazopyridinyl-aminopyridine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted imidazopyridinyl-aminopyridine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

  本发明涉及取代咪唑吡啶基-氨基吡啶化合物及合成这些化合物的方法。本发明还涉及含有取代咪唑吡啶基-氨基吡啶化合物的药物组合物，以及通过向需要的受试者施用这些化合物和药物组合物来治疗细胞增殖性疾病，如癌症的方法。
• 2-Imino-benzimidazoles
  申请人：Roth P. Gregory

  公开号：US20070232673A1

  公开（公告）日：2007-10-04

  Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.

  本发明涉及式（I）的新化合物或其药学上可接受的盐、前药和生物活性代谢物，其中取代基如本文所定义，其作为治疗剂具有用处。
• [EN] ATR INHIBITOR AND USE THEREOF<br/>[FR] INHIBITEUR D'ATR ET SON UTILISATION<br/>[ZH] ATR抑制剂及其用途
  申请人：CHENGDU EASTON BIOPHARMACEUTICALS CO LTD

  公开号：WO2022268025A1

  公开（公告）日：2022-12-29

  一类式I所示的具有ATR抑制作用的新化合物及其在制备药物中的用途。
• Toll-like receptor agonists
  申请人：The University of Kansas

  公开号：US10471139B2

  公开（公告）日：2019-11-12

  Compounds described herein can be used for therapeutic purposes. The compounds can be TLR agonists, such as TLR7 or TLR8 agonists. The compounds can be included in pharmaceutical compositions and used for therapies were being a TLR agonist is useful. The pharmaceutical compositions can include any ingredients, such as carries, diluents, excipients, fillers or the like that are common in pharmaceutical compositions. The compounds can be those illustrated or described herein as well as derivative thereof, prodrug thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combinations thereof. As such, the compounds can be used as adjuvants in vaccines as well as for other therapeutic purposes described herein. The compounds can have any one of the formulae. Examples of the compounds can be reviewed in Table 1 and Table A1 for activates.

  本文所述化合物可用于治疗目的。这些化合物可以是 TLR 激动剂，如 TLR7 或 TLR8 激动剂。这些化合物可包含在药物组合物中，用于治疗TLR激动剂有用的疾病。药物组合物可以包括任何成分，例如药物组合物中常见的载体、稀释剂、赋形剂、填料等。化合物可以是本文图示或描述的化合物，也可以是其衍生物、原药、盐或立体异构体，或在任何手性中心具有任何手性的化合物，或同系物、多晶型物、溶胶或其组合。因此，这些化合物可用作疫苗佐剂，也可用于本文所述的其他治疗目的。这些化合物可以具有任意一个式子。化合物的实例可参见表 1 和表 A1 中的活化剂。